Oligonucleotide development programs - started by Morten Lindow and Stine Mellerup, maintainable by everyone!!
Comments
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
$
%
123
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABCDEFGHIJKLM
1
Company namePartnerCompany Drug NameTargetDiseaseRoute
Developmental phase
Company name
PartnerCompany Drug NameTargetLinksArticles
2
AlnylamTekmiraALN-PCS01PCSK9HypercholessterolemiaintravenousPhase IAlnylamTekmiraALN-PCS02PCSK10http://www.alnylam.com/Programs-and-Pipeline/Alnylam-5x15/Hypercholestoralemia.php
3
AlnylamAscletis, TekmiraALN-VSPkinesin spindle protein/ KSP + vascular endothelial growth factor/VEGFLiver cancers
intravenous infusion
Phase IAlnylam
Ascletis, Tekmira
ALN-VSPkinesin spindle protein/ KSP + vascular endothelial growth factor/VEGFhttp://www.alnylam.com/Programs-and-Pipeline/Partner-Programs/Liver-Cancer.php
4
AlnylamTekmiraALN-TTRsctransthyretin geneTransthyretin-mediated amyloidosissubcutaneouslyPhase IAlnylamTekmiraALN-TTRsc
transthyretin gene
http://www.antisense.com.au/product-pipeline/atl1102-for-asthma/
5
AlnylamTekmiraALN-PCS02PCSK10HypercholessterolemiaintravenousPhase IAlnylamTekmiraALN-PCS03PCSK11http://www.antisense.com.au/product-pipeline/atl1101-for-prostate-cancer/
6
AlnylamAscletis, TekmiraALN-VSPkinesin spindle protein/ KSP + vascular endothelial growth factor/VEGFLiver cancers
intravenous infusion
Phase IAlnylam
Ascletis, Tekmira
ALN-VSPkinesin spindle protein/ KSP + vascular endothelial growth factor/VEGFhttp://www.arrowheadresearch.com/programs/ARC-520
7
AlnylamTekmiraALN-TTRsctransthyretin geneTransthyretin-mediated amyloidosissubcutaneouslyPhase ITekmiraALN-TTRsc
transthyretin gene
8
AlnylamTekmiraALN-TTRsctransthyretin geneTransthyretin-mediated amyloidosissubcutaneouslyPhase IAlnylamTekmiraALN-TTRsc
transthyretin gene
http://www.biopathholdings.com/content/product-pipeline/liposomal-bcl-2.htm
9
AlnylamTekmiraALN-PCS02PCSK10HypercholessterolemiaintravenousPhase IAlnylamTekmiraALN-PCS03PCSK11http://www.arrowheadresearch.com/programs/calaa-01
10
AlnylamAscletis, TekmiraALN-VSPkinesin spindle protein/ KSP + vascular endothelial growth factor/VEGFLiver cancers
intravenous infusion
Phase IAlnylam
Ascletis, Tekmira
ALN-VSPkinesin spindle protein/ KSP + vascular endothelial growth factor/VEGFhttp://enzon.com/docs/development_overview#jumpTop
11
AlnylamTekmiraALN-TTRsctransthyretin geneTransthyretin-mediated amyloidosissubcutaneouslyPhase IAlnylamTekmiraALN-TTRsc
transthyretin gene
http://www.parentprojectmd.org/site/PageServer?pagename=Advance_research_pipeline_gsk2402968 http://www.gsk.com/research/our-product-pipeline.html
12
AlnylamTekmiraALN-PCS02PCSK10HypercholessterolemiaintravenousPhase IAlnylamTekmiraALN-PCS03PCSK11http://www.gradalisinc.com/
13
AlnylamAscletis, TekmiraALN-VSPkinesin spindle protein/ KSP + vascular endothelial growth factor/VEGFLiver cancers
intravenous infusion
Phase IAlnylam
Ascletis, Tekmira
ALN-VSPkinesin spindle protein/ KSP + vascular endothelial growth factor/VEGFhttp://www.gradalisinc.com/
14
AlnylamTekmiraALN-TTRsctransthyretin geneTransthyretin-mediated amyloidosissubcutaneouslyPhase IAlnylamTekmiraALN-TTRsc
transthyretin gene
http://www.isip.com/Pipeline/Therapeutic-Areas/Cancer.htm#OGX 012
15
AlnylamTekmiraALN-TTR02transthyretin geneTransthyretin-mediated amyloidosisintravenousPhase IIAlnylamTekmiraALN-TTR03
transthyretin gene
http://www.alnylam.com/Programs-and-Pipeline/Alnylam-5x15/TTR-Amyloidosis.php
16
AlnylamKyowa Hakko KirinALN-RSV01
nucleocapsid N of the virus genome
Respiratory syncytial virus infectioninhalationPhase IIAlnylam
Kyowa Hakko Kirin
ALN-RSV02
nucleocapsid N of the virus genome
http://www.alnylam.com/Programs-and-Pipeline/Partner-Programs/index.php
17
AlnylamTekmiraALN-TTR03transthyretin geneTransthyretin-mediated amyloidosisintravenousPhase IIAlnylamTekmiraALN-TTR04
transthyretin gene
http://www.isip.com/Pipeline/Therapeutic-Areas/Neurodegenerative-Disease.htm
18
AlnylamTekmiraALN-TTR03transthyretin geneTransthyretin-mediated amyloidosisintravenousPhase IIAlnylamTekmiraALN-TTR04
transthyretin gene
http://enzon.com/docs/development_overview#jumpTop
19
AlnylamKyowa Hakko KirinALN-RSV02
nucleocapsid N of the virus genome
Respiratory syncytial virus infectioninhalationPhase IIAlnylam
Kyowa Hakko Kirin
ALN-RSV03
nucleocapsid N of the virus genome
http://enzon.com/docs/development_overview#jumpTop
20
AlnylamTekmiraALN-TTR03transthyretin geneTransthyretin-mediated amyloidosisintravenousPhase IIAlnylamTekmiraALN-TTR04
transthyretin gene
http://www.isip.com/Pipeline/Therapeutic-Areas/Inflammatory-Disease.htm
21
AlnylamKyowa Hakko KirinALN-RSV02
nucleocapsid N of the virus genome
Respiratory syncytial virus infectioninhalationPhase IIAlnylam
Kyowa Hakko Kirin
ALN-RSV03
nucleocapsid N of the virus genome
http://www.isip.com/Pipeline/Therapeutic-Areas/Metabolic-Disease.htm#ISIS-PTP1BRx
22
AlnylamALN-TMP
transmembrane protease, serine 6 (Tmprss6)
Hemoglobinopathies incl. beta-thalassemia and sickle cell anemia.
intravenouspre-clinicalAlnylamALN-TMP
transmembrane protease, serine 6 (Tmprss6)
http://www.alnylam.com/Programs-and-Pipeline/Alnylam-5x15/Hemoglobinopathies.php
23
AlnylamTekmiraALN-PCSscPCSK9Hypercholessterolemiasubcutaneouslypre-clinicalAlnylamTekmiraALN-PCSscPCSK10
24
AlnylamALN-CC5
complement component C5
paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic-uremic syndrome (aHUS), myasthenia gravis, neuromyelitis optica
subcutaneouslypre-clinicalAlnylamALN-CC6
complement component C6
http://www.alnylam.com/Programs-and-Pipeline/Alnylam-5x15/Complement-Mediated-Diseases.php
25
AlnylamALN-AT3
Antithrombin III/SERPINC1 + coagulation cascade
Hemophilia A and B and rare bleeding disorders
subcutaneouslypre-clinicalAlnylamALN-AT4
Antithrombin III/SERPINC1 + coagulation cascade
http://www.alnylam.com/Programs-and-Pipeline/Alnylam-5x15/Hemophilia.php
26
AlnylamALN-AS1
aminolevulinate synthase 1 (ALAS-1)
acute intermittent porphyriasubcutaneouslypre-clinicalAlnylamALN-AS2
aminolevulinate synthase 1 (ALAS-1)
http://www.alnylam.com/Programs-and-Pipeline/Alnylam-5x15/Porphyria.php
27
AlnylamALN-AAT
Alpha-1-Antitrypsin mutant/Z-AAT
Alpha-1-Antitrypsin Deficiency Associated Liver Disease
subcutaneouslypre-clinicalAlnylamALN-AAT
Alpha-1-Antitrypsin mutant/Z-AAT
http://www.alnylam.com/Programs-and-Pipeline/Alnylam-5x15/AAT-Deficiency.php
28
AlnylamALN-TMP
transmembrane protease, serine 6 (Tmprss6)
Hemoglobinopathies incl. beta-thalassemia and sickle cell anemia.
intravenouspre-clinicalAlnylamALN-TMP
transmembrane protease, serine 6 (Tmprss6)
http://www.genesignal.com/GS-101-Aganirsen-Clinical-Tr.32.0.html
29
AlnylamTekmiraALN-PCSscPCSK10Hypercholessterolemiasubcutaneouslypre-clinicalAlnylamTekmiraALN-PCSscPCSK11http://www.geron.com/imetelstat
30
AlnylamALN-TMP
transmembrane protease, serine 6 (Tmprss6)
Hemoglobinopathies incl. beta-thalassemia and sickle cell anemia.
intravenouspre-clinicalAlnylamALN-TMP
transmembrane protease, serine 6 (Tmprss6)
http://www.isip.com/Pipeline/Therapeutic-Areas/Neurodegenerative-Disease.htm
31
AlnylamTekmiraALN-PCSscPCSK10Hypercholessterolemiasubcutaneouslypre-clinicalAlnylamTekmiraALN-PCSscPCSK11http://www.isip.com/Pipeline/Therapeutic-Areas/Metabolic-Disease.htm#ISIS-PTP1BRx
32
AlnylamALN-CC6
complement component C6
paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic-uremic syndrome (aHUS), myasthenia gravis, neuromyelitis optica
subcutaneouslypre-clinicalAlnylamALN-CC7
complement component C7
http://www.isip.com/Pipeline/Therapeutic-Areas/Cardiovascular.htm#Mipomersen
33
AlnylamALN-AT4
Antithrombin III/SERPINC1 + coagulation cascade
Hemophilia A and B and rare bleeding disorders
subcutaneouslypre-clinicalAlnylamALN-AT5
Antithrombin III/SERPINC1 + coagulation cascade
http://www.isip.com/Pipeline/Therapeutic-Areas/Inflammatory-Disease.htm http://www.antisense.com.au/product-pipeline/atl1102-for-ms/
34
AlnylamALN-AS2
aminolevulinate synthase 1 (ALAS-1)
acute intermittent porphyriasubcutaneouslypre-clinicalAlnylamALN-AS3
aminolevulinate synthase 1 (ALAS-1)
http://www.isip.com/Pipeline/Therapeutic-Areas/Neurodegenerative-Disease.htm
35
AlnylamALN-AAT
Alpha-1-Antitrypsin mutant/Z-AAT
Alpha-1-Antitrypsin Deficiency Associated Liver Disease
subcutaneouslypre-clinicalAlnylamALN-AAT
Alpha-1-Antitrypsin mutant/Z-AAT
http://www.isip.com/Pipeline/Therapeutic-Areas/Cancer.htm#OGX 014
36
ISIS Pharmaceuticals
PfizerEXC 001
connective tissue growth factor(CTGF)
Local FibrosisPhase IIAntisensehttp://www.isip.com/Pipeline/Therapeutic-Areas/Inflammatory-Disease.htm
37
ISIS Pharmaceuticals
ISIS-CRPC- Reactive ProteinCoronary Artery DiseasePhase IIAntisensehttp://www.isip.com/Pipeline/Therapeutic-Areas/Cardiovascular.htm#Mipomersen
38
ISIS Pharmaceuticals
ISIS-APOCIIIApolipoprotein CIIIHypertriglyceridemiasubcutaneousPhase IIAntisensehttp://www.isip.com/Pipeline/Therapeutic-Areas/Cardiovascular.htm#Mipomersen
39
ISIS Pharmaceuticals
GSKISIS-TTRTransthyretin geneTransthyretin amyloidosissubcutaneouslyPhase IIIAntisensehttp://www.isip.com/Pipeline/Therapeutic-Areas/Neurodegenerative-Disease.htm
40
ISIS Pharmaceuticals
Teva Pharmaceutical Industries, OncoGenex
Custirsen/OGX-011clusterinCastrate resistant prostate cancer
intrevenous infusion
Phase IIIAntisenseNaked2'-O-MOEhttp://www.isip.com/Pipeline/Therapeutic-Areas/Cancer.htm#OGX 011
41
ISIS Pharmaceuticals
SanofiKYNAMRO/mipomersenApolipoprotein B 100Homozygous familial hypercholesterolemiasubcutaneousPhase IIIAntisenseNaked2'-O-MOE
approved by the FDA in the USA
http://www.isip.com/Pipeline/Therapeutic-Areas/Cardiovascular.htm#Mipomersen
42
ISIS Pharmaceuticals
GSKISIS-GSK
undisclosed target in viral infection
Viral infectionpre-clinicalAntisense
43
ISIS Pharmaceuticals
ISIS-PKKPrekallikrenHereditary Angioedemapre-clinicalAntisensehttp://www.isip.com/Pipeline/Therapeutic-Areas/Neurodegenerative-Disease.htm
44
ISIS Pharmaceuticals
XEN701hepcidinAnemia of chronic disorderspre-clinicalAntisense
45
ISIS Pharmaceuticals
Verva PharmaceuticalsISIS-FGFR4
Fibroblast growth factor receptor 4
Obesitypre-clinicalAntisensehttp://www.isip.com/Pipeline/Therapeutic-Areas/Metabolic-Disease.htm#ISIS-PTP1BRx
46
ISIS Pharmaceuticals
ISIS-FVIIFactor VIIClotting Disorderspre-clinicalAntisenseIScEthttp://www.isip.com/Pipeline/Therapeutic-Areas/Cardiovascular.htm#Mipomersen
47
ISIS Pharmaceuticals
ISIS-DGAT2
diacylglycerol acyltransferase-2
Nonalcoholic steatohepatitispre-clinicalAntisensehttp://www.isip.com/Pipeline/Therapeutic-Areas/Metabolic-Disease.htm#ISIS-PTP1BRx
48
ISIS Pharmaceuticals
ISIS-ANGPTL3Angiopoietin-like 3 proteinHyperlipidemiapre-clinicalAntisense
49
ISIS Pharmaceuticals
AstraZenecaISIS-AR/AZD5312Androgen receptorProstate Cancerpre-clinicalAntisenseIScEt
50
Lorus TherapeuticsLOR-2040
Ribonucleotide reductase subunit R2/RRM2
Myeloid leukemiaPhase IIAntisense
Waiting for partner for phase III
http://www.lorusthera.com/business-development/index.php
51
Marina BiotechCEQ508beta-cateninFamilial Adenomatous PolyposisoralPhase ItkRNAihttp://www.marinabio.com/FAP
52
Marina BiotechBladder Cancerintravesicalpre-clinicalsiRNAliposomeUsiRNAhttp://www.marinabio.com/pre_clinical_programs
53
Marina BiotechHepatocellular carcinomaintravenouspre-clinicaltauRNAitauRNAihttp://www.marinabio.com/pre_clinical_programs
54
miRagen Therapeutics
miR 92aPheripheral arterial diseasepre-clinicalanti-miRhttp://www.miragentherapeutics.com/pipeline/
55
miRagen Therapeutics
MGN-4893miR 451Polycythemia Verapre-clinicalanti-miRhttp://www.miragentherapeutics.com/7/Pipeline/
56
miRagen Therapeutics
miR 29Phathological fibrosispre-clinicalanti-miRhttp://www.miragentherapeutics.com/pipeline/
57
miRagen Therapeutics
ServierMGN-9103miR 208/499Chronic Heart Failurepre-clinicalanti-miRhttp://www.miragentherapeutics.com/7/Pipeline/
58
miRagen Therapeutics
ServierMGN-1374miR 15/195Post-Myocardial Infarction Remodelingpre-clinicalanti-miRhttp://www.miragentherapeutics.com/7/Pipeline/
59
miRagen Therapeutics
MGN-2667miR 145Cardiovascular diseasepre-clinicalanti-miR
60
Mirna TherapeuticsMRX34miR-34Liver cancerintravenousPhase ImiRNA mimicliposomehttp://www.mirnatherapeutics.com/___Pipeline/Pipeline_MRX34.aspx http://www.mirnatherapeutics.com/___Pipeline/Pipeline.aspx
61
OncoGenexISIS PharmaceuticalsApatorsen/OGX-427
Heat shock protein 27(Hsp27)
CancerinjectionPhase IIAntisense2'-O-MOEhttp://www.isip.com/Pipeline/Therapeutic-Areas/Cancer.htm#OGX 013
62
OncoGenexOGX-225
Insulin Growth Factor Binding Protein-2 and -5 (IGFBP-2, IGFBP-5)
Cancerpre-clinicalAntisense2'-O-MOEhttp://www.oncogenex.com/physicians/other-pipeline
63
PharmaxisASM8
CCR3 receptor, IL-3 and IL-5, GM-CSF
AsthmainhalationPhase IIsiRNAhttp://www.pharmaxis.com.au/research-development http://www.pharmaxis.com.au/assets/pdf/2011/2011_09_29_ASM8_enrolled.pdf
64
ProsensaPRO-045
Dystrophin gene, skip exon 45
Duchenne's Muscular DysrophyPhase II
Splicing modulation
Naked2'-O-Mehttp://www.prosensa.eu/technology-and-products/pipeline/pro045
65
ProsensaPRO-053
Dystrophin gene, skip exon 53
Duchenne's Muscular Dysrophypre-clinical
Splicing modulation
Naked2'-O-Mehttp://www.prosensa.eu/technology-and-products/pipeline/pro053
66
ProsensaPRO-135
CUG trinucleotide repeat in the non-coding region of the DMPK gene
Myotonic Dystrophypre-clinical
Splicing modulation
Naked2'-O-Mehttp://www.prosensa.eu/technology-and-products/pipeline/pro135-myotonic-dystrophy
67
ProsensaPRO-289
CAG trinucleotide repeat in the coding region of the HTT gene
Huntington's diseasepre-clinical
Splicing modulation
Naked2'-O-Mehttp://www.prosensa.eu/technology-and-products/pipeline/pro289-huntington%E2%80%99s-disease
68
Quark
Novartis, Silence Therapeutics, Alnylam
QPI-1002p53Acute Kidney InjuryintravenousPhase IsiRNAPlanned Phase IIhttp://silence-therapeutics.com/#!/pipeline/ http://www.quarkpharma.com/QBI-EN/products/qpi-1002da/
69
QuarkBioSpring GmbHQPI-1007Caspase 2non-arteritic ischemic optic neuropathyintravitrealPhase IsiRNAhttp://www.quarkpharma.com/qbi-en/products/qpi1007/
70
Quark
Pfizer, Silence Therapeutics, Alnylam pharmaceuticals
PF-4523655RTP801Age related Macular DegenerationintravitrealPhase IIsiRNAhttp://silence-therapeutics.com/#!/pipeline/ http://www.quarkpharma.com/QBI-EN/products/pf-655/
71
Quark
Novartis, Silence Therapeutics, Alnylam
QPI-1002p53Delayed graft functionintravenousPhase IIsiRNAhttp://silence-therapeutics.com/#!/pipeline/ http://www.quarkpharma.com/QBI-EN/products/qpi-1002da/
72
Quark
Pfizer, Silence Therapeutics, Alnylam pharmaceuticals
PF-04523655RTP802Diabetic Macular OedemaintravitrealPhase IIbsiRNAhttp://silence-therapeutics.com/#!/pipeline/ http://www.quarkpharma.com/QBI-EN/products/pf-655/
73
Regulus therapeutics
AstraZenecamicroRNA-33Atherosclerosispre-clinicalanti-miR
Studies in mice and non-human primates completed
74
Regulus therapeutics
microRNA-221Hepatocellular carcinomapre-clinicalanti-miRhttp://www.regulusrx.com/therapeutic-areas/#undefined
75
Regulus therapeutics
SanofimicroRNA-21Fibrosisinjectionpre-clinicalanti-miRhttp://www.regulusrx.com/therapeutic-areas/Nelson Chau et. Al. MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways
76
Regulus therapeutics
SanofimicroRNA-21Hepatocellular carcinomapre-clinicalanti-miR
77
Regulus therapeutics
GlaxoSmithKlinemicroRNA-122Hepatitis Cpre-clinicalanti-miRGalNAc
About to advance into clinical studies
78
Regulus therapeutics
Samsung Biomedical Research
microRNA-10bGlioblastomapre-clinicalanti-miR
79
Rexhan Pharmaceuticals
ArchexinAkt-1Solid tumorsPhase IIAntisensehttp://www.rexahn.com/cms/index.php/portfolio/archexintm/
80
RXi PharmaceuticalsRXI-109
Connective tissue growth factor
Dermal scarring and fibrosisintradermalPhase IsiRNAsd-rxRNA
Phase II planned to start in 2013
http://www.rxipharma.com/wp-content/uploads/2013/02/26FEB13_AsiaTIDES-2013_Karen-Bulock.pdf
81
RXi PharmaceuticalsRXI-109
Connective tissue growth factor
Occular disorders: Proliferative vitreoretinopathy
intravitrealpre-clinicalsiRNAsd-rxRNAhttp://www.rxipharma.com/pipeline/
82
RXi Pharmaceuticals
Connective tissue growth factor, MAP4K4
Occular disorders: Macular Degeneration and Retinoblastoma
pre-clinical
83
RXi PharmaceuticalsRXI-209Liver disease/Liver fibrosispre-clinical
84
SantarisSPC4955Apolipoprotein B-100HypercholessterolemiaPhase IAntisenseNakedhttp://www.santaris.com/product-pipeline
85
Santarismiravisen/SPC3649miR-122Hepatitis CinjectionPhase IIanti-miRNakedhttp://www.santaris.com/product-pipeline
86
SantarisPCSK9 ProgramPCSK9Hypercholessterolemiapre-clinicalAntisenseNakedhttp://www.santaris.com/product-pipeline
87
Sarepta Therapeutics
AVI-7288Marburg VirusesMarburg hemorrahic feverPhase IAntisenseNakedmorphilinohttp://www.sareptatherapeutics.com/our-programs/infectious-diseases/hemorrhagic-viruses/ http://www.pipelinereview.com/index.php/2012022847231/DNA-RNA-and-Cells/AVI-BioPharma-Announces-FDA-Approval-to-Proceed-With-a-Modified-Dosing-of-AVI-6003-for-Treatment-of-Marburg-Virus.html
88
Sarepta Therapeutics
AVI-7100Infection with Influenza AinfusionPhase IAntisenseNakedmorphilinohttp://www.sareptatherapeutics.com/our-programs/infectious-diseases/influenza/
89
Sarepta Therapeutics
GlaxoSmithKlineEteplirsen/AVI-4658
Dystrophin gene, skip exon 51
Duchenne's Muscular Dysrophylocal injectionPhase IIAntisenseNakedmorphilinohttp://www.sareptatherapeutics.com/our-programs/rare-diseases/duchenne-muscular-dystrophy/
90
Sarepta Therapeutics
SRP-4053
Dystrophin gene, skip exon 53
Duchenne's Muscular Dysrophypre-clinicalAntisenseNakedmorphilino
91
Sarepta Therapeutics
SRP-4050
Dystrophin gene, skip exon 50
Duchenne's Muscular Dysrophypre-clinicalAntisenseNakedmorphilino
92
Sarepta Therapeutics
SRP-4045
Dystrophin gene, skip exon 45
Duchenne's Muscular Dysrophypre-clinicalAntisenseNakedmorphilino
93
Silence Therapeutics
Atu027PKN3Solid tumorsPhase IsiRNAAtuPLEXhttp://silence-therapeutics.com/#!/pipeline/
94
Silence Therapeutics
Atu111
undisclosed target in the pulmonary vascular endothelium
Acute Lung Injurypre-clinicalsiRNADACC-siRNA
95
SilenseedsiG12D LODERK-RAS oncogenePancreatic cancerintatumoralPhase IIsiRNA
polymeric matrix
http://silenseed.com/page/224
96
SirnaomicsSTP601
VEGF, VEGFR1 and VEGFR2
Age related Macular Degeneration and Retinopathy
pre-clinicalsiRNAnanoparticleIND enablinghttp://a216530356.oinsite.yh.mynet.cn/_d272035471.htm
97
SirnaomicsSTP705TGFβ1 and Cox-2Skin Scarless Wound Healingpre-clinicalsiRNAnanoparticleIND enablinghttp://a216530356.oinsite.yh.mynet.cn/_d272035471.htm http://a216530356.oinsite.yh.mynet.cn/_d272035470.htm
98
SirnaomicsSTP503EGFR, Raf-1 and mTORBreast cancerpre-clinicalsiRNAnanoparticlehttp://a216530356.oinsite.yh.mynet.cn/_d272035471.htm
99
SirnaomicsSTP702
Conserved regions within the viral genome
Infection with Influenza A/H5N1inhalationpre-clinicalsiRNAnanoparticleIND enablinghttp://a216530356.oinsite.yh.mynet.cn/_d272035471.htm
100
SylentisSYL1001
Ocular pain associated with dry eye syndrome
occular topicalPhase IsiRNAhttp://www.clinicaltrials.gov/ct2/show/NCT01776658?term=rnai&rank=6
Loading...
 
 
 
Sheet1
Sheet2
Sheet3